TITLE:
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

CONDITION:
Hepatitis C, Chronic

INTERVENTION:
peginterferon alfa-2a [Pegasys]

SUMMARY:

      This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous
      intravenous (iv) drug users who have CHC and are currently enrolled in a methadone
      maintenance treatment program. The anticipated time on study treatment is 1-2 years, and the
      target sample size is <100 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  adult patients at least 18 years of age

          -  CHC infection, genotype 1, 2, or 3

          -  naive to treatment for CHC infection

          -  enrolled in a methadone maintenance program with documented attendance for at least 3
             months

          -  use of 2 forms of contraception during the study on both men and women

        Exclusion Criteria:

          -  previous treatment for CHC infection

          -  co-infection with human immunodeficiency virus (HIV)

          -  current use of IV or other illicit drugs

          -  decompensated cirrhosis

          -  women who are pregnant or breastfeeding
      
